Table 1.
Characteristics of the patients receiving salvage radiosurgery for recurrent Grade 3 or 4 glioma who did or did not receive adjuvant bevacizumab
| Total | −BVZ | +BVZ | |
|---|---|---|---|
| Number of patients | 63 | 21 | 42 |
| WHO grade | |||
| 3 | 14 | 5 | 9 |
| 4 | 49 | 16 | 33 |
| Sex | |||
| F | 18 | 7 | 11 |
| M | 45 | 14 | 31 |
| Median age (y) | 47 | 48 | 47 |
| Median follow–up (mo) | 6.5 | 5.3 | 7.8 |
| Median time from initial diagnosis to salvage SRS (mo) | 19.6 | 19.0 | 20.9 |
| Median KPS at time of SRS | 90 | 90 | 90 |
| Median KPS for WHO Grade 4 | 80 | 80 | 80 |
| Median SRS target volume (cc) | 4.8 | 5.6 | 4.5 |
| Mean number of systemic therapeutic agents before SRS | 3.6 | 3.5 | 3.7 |
| Mean number of systemic therapeutic agents after SRS | 2.9 | 1.1 | 3.8* |
Abbreviations: BVZ = bevacizumab; SRS = stereotactic radiosurgery; WHO = World Health Organization; KPS = Karnofsky performance status; adjuvant BVZ = treatment with BVZ concurrent with radiosurgery or afterward.
*
p < 0.05.